Interactive cost benefit model shows use of RDA in the neoadjuvant setting cost effective for German payers.

Breast cancer stakeholders attended the 34th Annual Meeting of the German Society for Senology conference featuring up-to-date breast cancer diagnostics and therapies. RDA was represented there via Assessment in Medicine (AiM).

AiM developed an interactive cost benefit model showing the adoption of RDA for response-guided therapy in the neoadjuvant setting provides significant potential savings to German healthcare payers. RDA determines early in a woman’s breast cancer treatment if she is responding to chemotherapy. If the chemotherapy is not working effectively she can be switched quickly to other treatment, avoiding the harmful side-effects of ineffective chemotherapy, improving her outcome.

“RDA is a critical tool for clinicians to manage chemotherapy for their patients. RDA assists in personalized treatment decisions, saves healthcare systems significant costs while improving outcomes for breast cancer patients,” said Dr. Ken Pritzker, President and CEO of Rna Diagnostics.

Presented by Tamlyn Rautenberg, Senior Research Consultant of AiM, the abstract and poster presented were entitled;To evaluate the economic impact of adopting RDA for response-guided treatment of breast cancer in the neoadjuvant setting in the German context. Interest at the conference was high for cost effective, novel diagnostic tools that allow for personalized treatment and more RDA data was requested.

The 34th Annual Meeting of the German Society for Senology was held June 19-21, 2014 at CityCube, Berlin, Germany and brought together over 2500 participants.

About Rna Diagnostics Inc.
Rna Diagnostics is a Canadian molecular diagnostics company developing diagnostic tools to improve chemotherapy management. The company’s first product, RNA Disruption Assay™ (RDA™), determines early in a woman’s breast cancer treatment if she is responding to chemotherapy. If the chemotherapy is not working effectively she can be switched quickly to other treatment, avoiding the harmful side-effects of ineffective chemotherapy and thereby improving her outcome. For more information on Rna Diagnostics, please visit www.rnadiagnostics.com